Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium

H Ding, CR Triggle - Vascular Health and Risk Management, 2005 - Taylor & Francis
Diabetes-associated vascular complications are collectively the major clinical problems
facing patients with diabetes and lead to the considerably higher mortality rate than that of …

The endothelium in health and disease-a target for therapeutic intervention

CR Triggle, M Hollenberg, TJ Anderson… - Journal of Smooth …, 2003 - jstage.jst.go.jp
In this review we discuss the contribution of NO, prostacyclin and endotheliumderived
relaxing factor—endothelium-derived hyperpolarizing factor, or EDHF, to vascular function …

[HTML][HTML] Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products

M Pannirselvam, WB Wiehler, T Anderson… - British journal of …, 2005 - ncbi.nlm.nih.gov
Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with
enhanced oxidative stress and cyclooxygenase products - PMC Back to Top Skip to main …

Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice

M Pannirselvam, H Ding, TJ Anderson… - European journal of …, 2006 - Elsevier
Endothelial dysfunction is considered as a major risk factor of cardiovascular complications
of type I and type II diabetes. Our previous studies have demonstrated that endothelial …

Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2

JJ McGuire, MD Hollenberg… - Canadian journal of …, 2004 - cdnsciencepub.com
L'activation du récepteur endothélial sensible aux protéinases (PAR-2) entraîne la
relaxation du muscle lisse vasculaire (MLV) et induit une hypotension par des mécanismes …

Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases

JJ McGuire - Current pharmaceutical design, 2004 - ingentaconnect.com
Proteinase-activated Receptor 2 (PAR2) is a potential target for the design of drug
treatments for vascular diseases. Its unique mechanism of activation by serine proteinases …

Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 …

CR Triggle, A Howarth, ZJ Cheng… - Canadian journal of …, 2005 - cdnsciencepub.com
Twenty-five years ago, the discovery of endothelium-derived relaxing factor opened a door
that revealed a new and exciting role for the endothelium in the regulation of blood flow and …

Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP

H Ding, AG Howarth, M Pannirselvam… - American Journal …, 2005 - journals.physiology.org
The Type 2 diabetic db/db mouse experiences vascular dysfunction typified by changes in
the contraction and relaxation profiles of small mesenteric arteries (SMAs). Contractions of …

The vascular endothelium in diabetes: a practical target fordrug treatment?

KL Andrews, M Pannirselvam… - Expert opinion on …, 2005 - Taylor & Francis
Vascular disease remains a major cause of morbidity and mortality in diabetes mellitus, in
spite of recent improvements in outcome, some of which may be modulated by improved …

The vasodilating effect of a Hintonia latiflora extract with antidiabetic action

C Vierling, CM Baumgartner, M Bollerhey, WD Erhardt… - Phytomedicine, 2014 - Elsevier
In the present study, it is shown for the first time that an extract of Hintonia latiflora (HLE)
which is used as an antidiabetic herbal medicine, is not only able to decrease blood glucose …